Cargando…

Potential Effects of Nutraceuticals in Retinopathy of Prematurity

Retinopathy of prematurity (ROP), the most common cause of childhood blindness, is a hypoxia-induced eye disease characterized by retinal neovascularization. In the normal retina, a well-organized vascular network provides oxygen and nutrients as energy sources to maintain a normal visual function;...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsang, Jessica K. W., Wolf, Susanne A., Pompoes, Inga M., Joussen, Antonia M., Lam, Wai Ching, Yang, Di, Lo, Amy C. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912639/
https://www.ncbi.nlm.nih.gov/pubmed/33499180
http://dx.doi.org/10.3390/life11020079
_version_ 1783656621827686400
author Tsang, Jessica K. W.
Wolf, Susanne A.
Pompoes, Inga M.
Joussen, Antonia M.
Lam, Wai Ching
Yang, Di
Lo, Amy C. Y.
author_facet Tsang, Jessica K. W.
Wolf, Susanne A.
Pompoes, Inga M.
Joussen, Antonia M.
Lam, Wai Ching
Yang, Di
Lo, Amy C. Y.
author_sort Tsang, Jessica K. W.
collection PubMed
description Retinopathy of prematurity (ROP), the most common cause of childhood blindness, is a hypoxia-induced eye disease characterized by retinal neovascularization. In the normal retina, a well-organized vascular network provides oxygen and nutrients as energy sources to maintain a normal visual function; however, it is disrupted when pathological angiogenesis is induced in ROP patients. Under hypoxia, inadequate oxygen and energy supply lead to oxidative stress and stimulate neovasculature formation as well as affecting the function of photoreceptors. In order to meet the metabolic needs in the developing retina, protection against abnormal vascular formation is one way to manage ROP. Although current treatments provide beneficial effects in reducing the severity of ROP, these invasive therapies may also induce life-long consequences such as systemic structural and functional complications as well as neurodevelopment disruption in the developing infants. Nutritional supplements for the newborns are a novel concept for restoring energy supply by protecting the retinal vasculature and may lead to better ROP management. Nutraceuticals are provided in a non-invasive manner without the developmental side effects associated with current treatments. These nutraceuticals have been investigated through various in vitro and in vivo methods and are indicated to protect retinal vasculature. Here, we reviewed and discussed how the use of these nutraceuticals may be beneficial in ROP prevention and management.
format Online
Article
Text
id pubmed-7912639
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79126392021-02-28 Potential Effects of Nutraceuticals in Retinopathy of Prematurity Tsang, Jessica K. W. Wolf, Susanne A. Pompoes, Inga M. Joussen, Antonia M. Lam, Wai Ching Yang, Di Lo, Amy C. Y. Life (Basel) Review Retinopathy of prematurity (ROP), the most common cause of childhood blindness, is a hypoxia-induced eye disease characterized by retinal neovascularization. In the normal retina, a well-organized vascular network provides oxygen and nutrients as energy sources to maintain a normal visual function; however, it is disrupted when pathological angiogenesis is induced in ROP patients. Under hypoxia, inadequate oxygen and energy supply lead to oxidative stress and stimulate neovasculature formation as well as affecting the function of photoreceptors. In order to meet the metabolic needs in the developing retina, protection against abnormal vascular formation is one way to manage ROP. Although current treatments provide beneficial effects in reducing the severity of ROP, these invasive therapies may also induce life-long consequences such as systemic structural and functional complications as well as neurodevelopment disruption in the developing infants. Nutritional supplements for the newborns are a novel concept for restoring energy supply by protecting the retinal vasculature and may lead to better ROP management. Nutraceuticals are provided in a non-invasive manner without the developmental side effects associated with current treatments. These nutraceuticals have been investigated through various in vitro and in vivo methods and are indicated to protect retinal vasculature. Here, we reviewed and discussed how the use of these nutraceuticals may be beneficial in ROP prevention and management. MDPI 2021-01-22 /pmc/articles/PMC7912639/ /pubmed/33499180 http://dx.doi.org/10.3390/life11020079 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tsang, Jessica K. W.
Wolf, Susanne A.
Pompoes, Inga M.
Joussen, Antonia M.
Lam, Wai Ching
Yang, Di
Lo, Amy C. Y.
Potential Effects of Nutraceuticals in Retinopathy of Prematurity
title Potential Effects of Nutraceuticals in Retinopathy of Prematurity
title_full Potential Effects of Nutraceuticals in Retinopathy of Prematurity
title_fullStr Potential Effects of Nutraceuticals in Retinopathy of Prematurity
title_full_unstemmed Potential Effects of Nutraceuticals in Retinopathy of Prematurity
title_short Potential Effects of Nutraceuticals in Retinopathy of Prematurity
title_sort potential effects of nutraceuticals in retinopathy of prematurity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912639/
https://www.ncbi.nlm.nih.gov/pubmed/33499180
http://dx.doi.org/10.3390/life11020079
work_keys_str_mv AT tsangjessicakw potentialeffectsofnutraceuticalsinretinopathyofprematurity
AT wolfsusannea potentialeffectsofnutraceuticalsinretinopathyofprematurity
AT pompoesingam potentialeffectsofnutraceuticalsinretinopathyofprematurity
AT joussenantoniam potentialeffectsofnutraceuticalsinretinopathyofprematurity
AT lamwaiching potentialeffectsofnutraceuticalsinretinopathyofprematurity
AT yangdi potentialeffectsofnutraceuticalsinretinopathyofprematurity
AT loamycy potentialeffectsofnutraceuticalsinretinopathyofprematurity